In this interview, Technology Networks spoke with Gene Mack, chief executive officer and president of Gain Therapeutics, to ...
In a recent study posted to the bioRxiv* pre-print server, researchers investigated allosteric binders of angiotensin-converting enzyme 2 (ACE2) that significantly inhibit severe acute respiratory ...
Profs Ravi Acharya and Edward Sturrock review the historical foundation, present landscape and future clinical promise of ACE inhibition.
HotSpot Therapeutics is debuting with $45 million from Atlas Venture and Sofinnova Partners to explore allosteric inhibitors against tough-to-drug targets. The Cambridge, Mass.-based biotech firm will ...
BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials. Background: ...
Chemistry professors used the Google algorithm PageRank to identify key amino acids in the regulation of a bacterial enzyme essential for most microorganisms. Yale scientists have taken a novel ...
According to a recently published research paper by a team of scientists, a groundbreaking approach has been developed to create artificial allosteric sites (where by binding an effector molecule, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback